 Glomerulonephritis, Membranoproliferative
"Glomerulonephritis, Membranoproliferative" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Chronic glomerulonephritis characterized histologically by proliferation of MESANGIAL CELLS, increase in the MESANGIAL EXTRACELLULAR MATRIX, and a thickening of the glomerular capillary walls. This may appear as a primary disorder or secondary to other diseases including infections and autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Various subtypes are classified by their abnormal ultrastructures and immune deposits. Hypocomplementemia is a characteristic feature of all types of MPGN.
| Descriptor ID |
D015432
|
| MeSH Number(s) |
C12.777.419.570.363.615 C13.351.968.419.570.363.615 C20.425
|
| Concept/Terms |
Glomerulonephritis, Membranoproliferative- Glomerulonephritis, Membranoproliferative
- Glomerulonephritides, Membranoproliferative
- Membranoproliferative Glomerulonephritides
- Glomerulonephritis, Mesangiocapillary
- Glomerulonephritides, Mesangiocapillary
- Mesangiocapillary Glomerulonephritides
- MPGN
- Membranoproliferative Glomerulonephritis
- Mesangiocapillary Glomerulonephritis
- Glomerulonephritis, Hypocomplementemic
- Glomerulonephritides, Hypocomplementemic
- Hypocomplementemic Glomerulonephritides
- Hypocomplementemic Glomerulonephritis
Membranoproliferative Glomerulonephritis, Type I- Membranoproliferative Glomerulonephritis, Type I
- Subendothelial Membranoproliferative Glomerulonephritis
- Membranoproliferative Glomerulonephritis, Subendothelial
- Mesangiocapillary Glomerulonephritis, Type I
|
Below are MeSH descriptors whose meaning is more general than "Glomerulonephritis, Membranoproliferative".
Below are MeSH descriptors whose meaning is more specific than "Glomerulonephritis, Membranoproliferative".
This graph shows the total number of publications written about "Glomerulonephritis, Membranoproliferative" by people in this website by year, and whether "Glomerulonephritis, Membranoproliferative" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 | | 1997 | 1 | 0 | 1 | | 2004 | 1 | 1 | 2 | | 2007 | 1 | 0 | 1 | | 2008 | 0 | 1 | 1 | | 2015 | 1 | 0 | 1 | | 2021 | 1 | 0 | 1 | | 2022 | 3 | 0 | 3 | | 2023 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Glomerulonephritis, Membranoproliferative" by people in Profiles.
-
Antonucci L, Thurman JM, Vivarelli M. Complement inhibitors in pediatric kidney diseases: new therapeutic opportunities. Pediatr Nephrol. 2024 May; 39(5):1387-1404.
-
Nester C, Appel GB, Bomback AS, Bouman KP, Cook HT, Daina E, Dixon BP, Rice K, Najafian N, Hui J, Podos SD, Langman CB, Lightstone L, Parikh SV, Pickering MC, Sperati CJ, Trachtman H, Tumlin J, de Vries AP, Wetzels JFM, Remuzzi G. Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies. Am J Nephrol. 2022; 53(10):687-700.
-
Podos SD, Trachtman H, Appel GB, Bomback AS, Dixon BP, Wetzels JFM, Cook HT, Parikh SV, Pickering MC, Tumlin J, Langman CB, Lightstone L, Sperati CJ, Daina E, Bouman KP, Rice K, Thanassi JA, Huang M, Nester C, Remuzzi G. Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor Danicopan. Am J Nephrol. 2022; 53(10):675-686.
-
Li A, Ambruso SL, Oto OA, Barry M, Edelstein CL. A case report of pre-eclampsia-like endothelial injury in the kidney of an 85-year-old man treated with ibrutinib. BMC Nephrol. 2022 07 23; 23(1):264.
-
Vivarelli M, van de Kar N, Labbadia R, Diomedi-Camassei F, Thurman JM. A clinical approach to children with C3 glomerulopathy. Pediatr Nephrol. 2022 03; 37(3):521-535.
-
Rajasekaran A, Ngo TT, Abdelrahim M, Glass W, Podoll A, Verstovsek S, Abudayyeh A. Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib. BMC Nephrol. 2015 Aug 01; 16:121.
-
Holers VM. The spectrum of complement alternative pathway-mediated diseases. Immunol Rev. 2008 Jun; 223:300-16.
-
Smith RJ, Alexander J, Barlow PN, Botto M, Cassavant TL, Cook HT, de C?rdoba SR, Hageman GS, Jokiranta TS, Kimberling WJ, Lambris JD, Lanning LD, Levidiotis V, Licht C, Lutz HU, Meri S, Pickering MC, Quigg RJ, Rops AL, Salant DJ, Sethi S, Thurman JM, Tully HF, Tully SP, van der Vlag J, Walker PD, W?rzner R, Zipfel PF. New approaches to the treatment of dense deposit disease. J Am Soc Nephrol. 2007 Sep; 18(9):2447-56.
-
M?hlfeld AS, Segerer S, Hudkins K, Farr AG, Bao L, Kraus D, Holers VM, Quigg RJ, Alpers CE. Overexpression of complement inhibitor Crry does not prevent cryoglobulin-associated membranoproliferative glomerulonephritis. Kidney Int. 2004 Apr; 65(4):1214-23.
-
Elliott MK, Jarmi T, Ruiz P, Xu Y, Holers VM, Gilkeson GS. Effects of complement factor D deficiency on the renal disease of MRL/lpr mice. Kidney Int. 2004 Jan; 65(1):129-38.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|